NCT03435991

Brief Summary

Rationale: The overactive bladder syndrome is diagnosed clinically by using the ICS criteria of ≥8 micturitions and at least 1 urgency episode per 24 hours. To determine whether patients fit the criteria, micturition diaries ('sensation-related bladder diaries') and other symptom questionnaires with considerable limitations are used. This makes it difficult to get a good impression of the fluctuation of complaints during the day / week. These limitations are overcome using the Experience Sampling Method (ESM). This is an electronic questioning method which is characterized by repeated and random, momentary assessments in the subject's current environment and state. This study follows other successful ESM studies done within the Gastroenterology and Psychiatry Department. The aim of this study is to evaluate if the ESM is more accurate in the assessment of urological complaints in OAB compared to the current assessment with the use of the sensations-related bladder diaries (SR-BDs) and retrospective questionnaires. Furthermore the aim is to assess the reliability and validity of this OAB-specific electronic patient-reported outcome measure (ePRO), based on the Experience Sampling Method-principle, for symptom assessment and assessment of triggers for symptoms in OAB. Objective: To evaluate the accuracy of the ESM to assess urological complaints in OAB compared to SR-BDs and retrospective questionnaires. To assess content validity, reliability and the accuracy to validate the developed ePRO in OAB patients. Study design: The ESM study is a multicentre, prospective, cross-sectional study. Study population: 66 OAB patients will be recruited at the outpatient Pelvic Care Centre in Maastricht UMC+, Zuyderland Hospital and University Hospital Antwerp, 66 healthy volunteers will be recruited as well. Methods: In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period. Main study endpoints: The main study outcome comprehends the psychometric properties of the PROM for symptom assessment of OAB symptoms. Secondary outcomes are increase in ESM score for OAB symptoms and environmental and psychosocial factors (e.g. as measured by the PROM) from one time point (t-1) to the next (t).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
132

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 8, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 19, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

August 6, 2018

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 5, 2021

Completed
Last Updated

February 21, 2020

Status Verified

February 1, 2020

Enrollment Period

2.4 years

First QC Date

February 8, 2018

Last Update Submit

February 19, 2020

Conditions

Keywords

Experience Sampling MethodEcological Momentary AssessmentMomentary Symptom AssessmentPatient Reported Outcome Measure

Outcome Measures

Primary Outcomes (2)

  • Urgency (ESM score)

    Urgency scores as measured by the Experience Sampling Method tool (i.e. momentary measurement)

    2 years

  • Urgency (SR-BD score)

    Urgency scores as measured by the sensation-related bladder diary (i.e. retrospective measurement with a recall period of several minutes)

    2 years

Secondary Outcomes (7)

  • Symptom scores (other than urgency) as measured using the ESM tool

    2 years

  • OABq symptom score

    2 years

  • ICIQ-FLUTS symptom score

    2 years

  • 3IQ symptom score

    2 years

  • ICIQ-MLUTS symptom score

    2 years

  • +2 more secondary outcomes

Study Arms (2)

OAB patients

Other: Validation Experience Sampling Method 'Uromate'

Healthy volunteers

Other: Validation Experience Sampling Method 'Uromate'

Interventions

In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.

Healthy volunteersOAB patients

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Thirty-three male and thirty-three female OAB patients will be recruited at the outpatient Pelvic Care Centre in Maastricht UMC+ and at the outpatient clinic of Zuyderland Hospital and University Hospital Antwerp. Patients will be diagnosed with OAB by their urologist using the ICS criteria for OAB. Furthermore, thirty-five male and thirty-five female healthy volunteers will be included in order to exploratively evaluate the ability of ESM to discriminate between OAB patients and healthy controls, in terms of triggers for the occurrence and/or persistence of urological symptoms. This control group will be sex- and age-matched to the group of OAB patients.

You may qualify if:

  • Age between 18 and 70 years;
  • Male and female
  • Ability to understand and speak Dutch;
  • Ability to understand how to utilize the ESM tool.

You may not qualify if:

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Patients with a clear anatomical or other urological cause for OAB (e.g. bladder cancer, benign prostate hyperplasia (BPH), prostate cancer, urolithiasis, chronic or acute urinary tract infections (UTI), neurological disease).
  • Patient with severe stress incontinence
  • Pregnancy
  • Current or past diagnosis of lower urinary tract symptoms;
  • No more than one urinary tract infection in half a year.
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht Univeristy Medical Center+

Maastricht, Netherlands

RECRUITING

Related Publications (29)

  • Mujagic Z, Leue C, Vork L, Lousberg R, Jonkers DM, Keszthelyi D, Hesselink MA, van Schagen TJ, van Os J, Masclee AA, Kruimel JW. The Experience Sampling Method--a new digital tool for momentary symptom assessment in IBS: an exploratory study. Neurogastroenterol Motil. 2015 Sep;27(9):1295-302. doi: 10.1111/nmo.12624. Epub 2015 Jun 22.

    PMID: 26100684BACKGROUND
  • Simons CJ, Hartmann JA, Kramer I, Menne-Lothmann C, Hohn P, van Bemmel AL, Myin-Germeys I, Delespaul P, van Os J, Wichers M. Effects of momentary self-monitoring on empowerment in a randomized controlled trial in patients with depression. Eur Psychiatry. 2015 Nov;30(8):900-6. doi: 10.1016/j.eurpsy.2015.09.004. Epub 2015 Oct 6.

    PMID: 26647864BACKGROUND
  • Verhagen SJ, Hasmi L, Drukker M, van Os J, Delespaul PA. Use of the experience sampling method in the context of clinical trials. Evid Based Ment Health. 2016 Aug;19(3):86-9. doi: 10.1136/ebmental-2016-102418.

    PMID: 27443678BACKGROUND
  • van Os J, Verhagen S, Marsman A, Peeters F, Bak M, Marcelis M, Drukker M, Reininghaus U, Jacobs N, Lataster T, Simons C; ESM-MERGE Investigators PhD; Lousberg R, Guloksuz S, Leue C, Groot PC, Viechtbauer W, Delespaul P. The experience sampling method as an mHealth tool to support self-monitoring, self-insight, and personalized health care in clinical practice. Depress Anxiety. 2017 Jun;34(6):481-493. doi: 10.1002/da.22647. Epub 2017 May 23.

    PMID: 28544391BACKGROUND
  • Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. No abstract available.

    PMID: 11857671BACKGROUND
  • Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011 May;77(5):1081-7. doi: 10.1016/j.urology.2010.08.039. Epub 2011 Jan 22.

    PMID: 21256571BACKGROUND
  • Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. doi: 10.1046/j.1464-410x.2001.02228.x.

    PMID: 11412210BACKGROUND
  • Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. doi: 10.1007/s00345-002-0301-4. Epub 2002 Nov 15.

    PMID: 12811491BACKGROUND
  • Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. doi: 10.1016/j.eururo.2006.09.019. Epub 2006 Oct 2.

    PMID: 17049716BACKGROUND
  • Coyne KS, Matza LS, Brewster-Jordan J. "We have to stop again?!": The impact of overactive bladder on family members. Neurourol Urodyn. 2009;28(8):969-75. doi: 10.1002/nau.20705.

    PMID: 19301410BACKGROUND
  • Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011 Oct;108(7):1132-8. doi: 10.1111/j.1464-410X.2010.09993.x. Epub 2011 Jan 13.

    PMID: 21231991BACKGROUND
  • Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, Corey R, Zhou SZ, Hunt TL. Estimated economic costs of overactive bladder in the United States. Urology. 2003 Jun;61(6):1123-8. doi: 10.1016/s0090-4295(03)00009-8.

    PMID: 12809878BACKGROUND
  • Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009 Mar;15(4 Suppl):S98-S107.

    PMID: 19355804BACKGROUND
  • Foley AL, Loharuka S, Barrett JA, Mathews R, Williams K, McGrother CW, Roe BH. Association between the Geriatric Giants of urinary incontinence and falls in older people using data from the Leicestershire MRC Incontinence Study. Age Ageing. 2012 Jan;41(1):35-40. doi: 10.1093/ageing/afr125. Epub 2011 Sep 24.

    PMID: 21948857BACKGROUND
  • Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. Affective symptoms and the overactive bladder - a systematic review. J Psychosom Res. 2015 Feb;78(2):95-108. doi: 10.1016/j.jpsychores.2014.11.019. Epub 2014 Nov 27.

    PMID: 25499886BACKGROUND
  • Melville JL, Delaney K, Newton K, Katon W. Incontinence severity and major depression in incontinent women. Obstet Gynecol. 2005 Sep;106(3):585-92. doi: 10.1097/01.AOG.0000173985.39533.37.

    PMID: 16135592BACKGROUND
  • Litman HJ, Steers WD, Wei JT, Kupelian V, Link CL, McKinlay JB; Boston Area Community Health Survey Investigators. Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey. Urology. 2007 Nov;70(5):916-21. doi: 10.1016/j.urology.2007.06.1117. Epub 2007 Oct 24.

    PMID: 17919693BACKGROUND
  • Choi EP, Lam CL, Chin WY. Mental Health Mediating the Relationship Between Symptom Severity and Health-Related Quality of Life in Patients with Lower Urinary Tract Symptoms. Low Urin Tract Symptoms. 2016 Sep;8(3):141-9. doi: 10.1111/luts.12086. Epub 2015 Feb 12.

    PMID: 27619778BACKGROUND
  • Martin S, Vincent A, Taylor AW, Atlantis E, Jenkins A, Januszewski A, O'Loughlin P, Wittert G. Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS One. 2015 Oct 7;10(10):e0137903. doi: 10.1371/journal.pone.0137903. eCollection 2015.

    PMID: 26445118BACKGROUND
  • Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1-32. doi: 10.1146/annurev.clinpsy.3.022806.091415.

    PMID: 18509902BACKGROUND
  • Myin-Germeys I, Oorschot M, Collip D, Lataster J, Delespaul P, van Os J. Experience sampling research in psychopathology: opening the black box of daily life. Psychol Med. 2009 Sep;39(9):1533-47. doi: 10.1017/S0033291708004947. Epub 2009 Feb 12.

    PMID: 19215626BACKGROUND
  • Houtveen JH, Oei NY. Recall bias in reporting medically unexplained symptoms comes from semantic memory. J Psychosom Res. 2007 Mar;62(3):277-82. doi: 10.1016/j.jpsychores.2006.11.006.

    PMID: 17324676BACKGROUND
  • Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003 Apr;24(2):182-99. doi: 10.1016/s0197-2456(02)00320-3.

    PMID: 12689739BACKGROUND
  • Moskowitz DS, Young SN. Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology. J Psychiatry Neurosci. 2006 Jan;31(1):13-20.

    PMID: 16496031BACKGROUND
  • Hartmann JA, Wichers M, Menne-Lothmann C, Kramer I, Viechtbauer W, Peeters F, Schruers KR, van Bemmel AL, Myin-Germeys I, Delespaul P, van Os J, Simons CJ. Experience sampling-based personalized feedback and positive affect: a randomized controlled trial in depressed patients. PLoS One. 2015 Jun 2;10(6):e0128095. doi: 10.1371/journal.pone.0128095. eCollection 2015.

    PMID: 26034983BACKGROUND
  • Wichers M, Simons CJ, Kramer IM, Hartmann JA, Lothmann C, Myin-Germeys I, van Bemmel AL, Peeters F, Delespaul P, van Os J. Momentary assessment technology as a tool to help patients with depression help themselves. Acta Psychiatr Scand. 2011 Oct;124(4):262-72. doi: 10.1111/j.1600-0447.2011.01749.x. Epub 2011 Aug 13.

    PMID: 21838742BACKGROUND
  • Broen MP, Marsman VA, Kuijf ML, Van Oostenbrugge RJ, van Os J, Leentjens AF. Unraveling the Relationship between Motor Symptoms, Affective States and Contextual Factors in Parkinson's Disease: A Feasibility Study of the Experience Sampling Method. PLoS One. 2016 Mar 10;11(3):e0151195. doi: 10.1371/journal.pone.0151195. eCollection 2016.

    PMID: 26962853BACKGROUND
  • Palmier-Claus JE, Myin-Germeys I, Barkus E, Bentley L, Udachina A, Delespaul PA, Lewis SW, Dunn G. Experience sampling research in individuals with mental illness: reflections and guidance. Acta Psychiatr Scand. 2011 Jan;123(1):12-20. doi: 10.1111/j.1600-0447.2010.01596.x. Epub 2010 Aug 16.

    PMID: 20712828BACKGROUND
  • Alrubaiy L, Hutchings HA, Williams JG. Assessing patient reported outcome measures: A practical guide for gastroenterologists. United European Gastroenterol J. 2014 Dec;2(6):463-70. doi: 10.1177/2050640614558345.

    PMID: 25452841BACKGROUND

MeSH Terms

Conditions

Urinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesLower Urinary Tract SymptomsUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Desiree Vrijens, MD, PhD

    Maastricht University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexandra Herrewegh, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2018

First Posted

February 19, 2018

Study Start

August 6, 2018

Primary Completion

January 5, 2021

Study Completion

January 5, 2021

Last Updated

February 21, 2020

Record last verified: 2020-02

Locations